In this cohort of relapsed/refractory Burkitt lymphoma patients, the prognostic impact of mutations in TP53, MYC, ID3, CCND3, KRAS, and FAT4 remains unclear. This evidence concerns the gene CCND3 and Burkitt lymphoma.